Cipher Pharmaceuticals Inc. announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland ("Bausch Health") relating to the License,Development and Commercialization Agreement (the "Agreement") of Trulance. As previously disclosed, the Company received a notice of termination from Bausch Health for alleged breach of contract in respect of its licensing agreement for Trulance. The arbitration award holds that Cipher was in breach of contract and will be required to turn over the Canadian Drug Identification Number ("DIN") for Trulance to Bausch Health effective immediately. In addition, Cipher has been ordered to pay approximately $240,000 related to unpaid invoices associated with work which was previously completed by Bausch Health. The issue of whether Bausch Health is entitled to any additional amounts under the Agreement is deferred to a subsequent phase of the arbitration. As a result, the company will impair approximately $5,400,000 in intangible assets related to upfront and milestone payments paid.